Clarivate Widens Alliance with VeriSIM Life For Drug Development

Clarivate Plc, a worldwide leader in connecting people and companies to trusted knowledge to alter their environment, has announced the debut of the VeriSIM Life Translational Index on Cortellis Drug Discovery knowledge by Clarivate. Customers benefit from a wide range of predicted compound safety and effectiveness insights, including as bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dosage, and more, thanks to the integrated workflow.

The new solution serves as the next phase of an expanding partnership between Clarivate and VeriSIM Life, the leading artificial intelligence (AI)-enabled, R&D decisions de-risker for breakthrough drug development, announced earlier this year, as per pharmabiz.

Robert Poolman, senior vice president life sciences & healthcare products, Clarivate, said: "As emerging technology continues to evolve to address the growing needs of biotechs, pharmas and patients alike, drug developers can leverage AI to reduce research and development time and increase clinically active compound candidates, all while meeting government regulations and standards. In partnership with VeriSIM Life, the Translational Index for Clarivate leverages AI to address these unmet needs, improving pre-clinical success rates and ultimately equipping our customers with the insight and foresight needed to create innovative treatments, deliver them to patients faster and create a healthier tomorrow."

Jo Varshney, CEO & founder, VeriSIM Life, commented: "The science of translating medicinal candidates to safe and effective therapies is extremely complex. We recognize that researchers need solutions which complement their workflows and scientific methods while improving the probability of clinical success. The expansion of our integration with Clarivate is natural evolution for scientific discovery within research organizations advancing the next generation of life saving medicines. It also allows drug program owners to manage the risk of asset development much more effectively."

The FDA considers the costs and time required to translate medication ideas into good clinical trial outcomes to be "unsustainable" for the pharmaceutical sector.